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Oxidative stress and inflammation are closely involved in the 
pathogenesis of ageing and chronic degenerative diseases, 
including cardiovascular and neurodegenerative diseases as well 
as cancer.
1,2
  Therefore, a strategy has been proposed with the 
aim of reducing oxidative stress and inflammation in order to 
inhibit or retard aging and carcinogenesis.  The redox-sensitive 
signaling system known as the Keap1/Nrf2/ARE (Kelch-like 
ECH-associated protein 1/NF-E2 p45-related factor 2/antioxidant 
response element) pathway plays a key role in maintenance of 
cellular homeostasis under stress, inflammatory, carcinogenic, 
and proapoptotic conditions.  Electrophilic agents oxidize highly 
reactive cysteine residues of the protein sensor for inducers, 
Keap1, leading to a conformation change that allows the 
transcription factor Nrf2 to accumulate and undergo nuclear 
translocation and binding (as a heterodimer with a small Maf 
protein) to the AREs, specific DNA sequences present in the 
promoter/enhancer regions of cytoprotective genes.
3-5
  These 
processes enhance transcription of ARE-regulated anti-
inflammatory and cytoprotective enzymes.  Thus, activators of 
the Keap1/Nrf2/ARE pathway (briefly, Nrf2 activators) are  
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considered to be potential cytoprotective and anti-inflammatory 
agents. 
Reversible covalent drugs, which bind to their protein targets 
but not permanently, combine the advantages and circumvent the 
disadvantages of irreversible covalent and reversible non- 
covalent drugs.  These compounds demonstrate unique biological 
features by selectively targeting protein cysteine residues in a 
reversible covalent fashion,
6,7
 avoiding off-target drug 
interactions. Owing to the reversible nature of the reaction, 
toxicity issues commonly associated with covalent protein 
modifications can be minimized.  However, reversible covalent 
drugs have been largely ignored because of the lack of reactive 
compounds to produce the reversible covalent adducts with 
protein targets.  Based on previously published evidence,
8,9
 the 
nonenolizable cyanoenone functionality is considered to be one 
of the best fragments that can be used for exploring reversible 
covalent drugs which are targeting the Keap1/Nrf2/ARE 
pathway.  Although the reversible Michael adducts involved in 
equilibrium mixtures have been observed in solution by NMR, 
UV, and mass spectrometry, they have never been isolated and 
structurally characterized because of the rapid equilibrium that 
favors the reverse reaction.
8–10
  Most recently, a 3D structure of a 
reversible thiol Michael adduct was observed in situ in a 
crystalline sponge.
11
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Tricyclic, bicyclic, and monocyclic compounds containing cyanoenones induce various anti-
inflammatory and cytoprotective enzymes through activation of the Keap1/Nrf2/ARE 
(antioxidant response element) pathway.  The potency of these compounds as Nrf2 activators 
was determined using a prototypic cytoprotective enzyme NAD(P)H:quinone oxidoreductase 1 
(NQO1) in Hepa1c1c7 murine hepatoma cells.  The electron affinity (EA) of the compounds, 
expressed as the energy of their lowest unoccupied molecular orbital [E (LUMO)], was 
evaluated using two types of quantum mechanical calculations: the semiempirical (AM1) and 
the density functional theory (DFT) methods.  We observed striking linear correlations [r  = 
0.897 (AM1) and 0.936 (DFT)] between NQO1 inducer potency of these compounds and their E 
(LUMO) regardless of the molecule size.  Importantly and interestingly, this finding 
demonstrates that the EA is the essentially important factor that determines the reactivity of the 
cyanoenones with Keap1.  
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Presently, a Nrf2 activator, bardoxolone methyl (Figure 1), 
which is a semisynthestic triterpenoid with cyanoenone 
functionality in ring A and a reversible covalent drug,
8
 has been 
evaluated in Phase II clinical trials for the treatment of PAH 
(pulmonary arterial hypertension) in the USA
12
 and diabetic 
nephropathy in Japan
13
.  During the development of bardoxolone 
methyl and its analogues, tri-, bi-, and monocyclic compounds 
with cyanoenones have been designed and explored.
9,10,14
  They 
are also highly potent Nrf2 activators and reversible covalent 
drugs.  Amongst them, tricyclic compound 1 (TBE-31, Figure 1 
and Table 1) is the most potent Nrf2 activator.
14
  Although 1 was 
initially designed based on bardoxolone methyl, 1 is not a simple 
mimic since 1 is not a triterpenoid but a tricyclic compound, with 
two cyanoenones in rings A and C, and an ethynyl group at C10a.  
To understand such high biological potency of 1 in a series of tri-
, bi-, and monocyclic compounds with cyanoenones, we have 
focused on the electron affinity of these compounds expressed as 
the energy of their lowest unoccupied molecular orbital [E 
(LUMO)] because it has been previously reported that electron 
affinity is a major molecular property for determining the 
potency of bardoxolone methyl analogues, semisynthetic 
triterpenoids, as Nrf2 activators.
15
  We have found that 1 has 
extremely low E (LUMO) among them.  Also, notably, we have 
observed striking linear correlations between the inducer potency 
of the compounds and their E (LUMO) regardless of the 
molecule size.  We now report these interesting quantitative 
structure–activity relationships (QSAR) in this communication.  
 
 
Figure 1. Structures of bardoxolone methyl and TBE-31 
 
The potency of tri-, bi-, and monocyclic compounds 
containing cyanoenones as Nrf2 activators was evaluated using a 
prototypic cytoprotective enzyme NAD(P)H:quinone 
oxidoreductase 1 (NQO1) in Hepa1c1c7 murine hepatoma cells 
by CD values (the concentration required to double the specific 
enzyme activity of NQO1).
9,10,14
  For this study, the pCD values 
(logarithm of the reciprocal of CD values expressed in M (mol/L) 
units) are employed for inducer potency. NQO1 is the 
prototypical Nrf2 target gene, and the NQO1 bioassay is widely 
recognized as a highly quantitative readout for Nrf2 activity. To 
our knowledge, the cyanoenones are not direct substrates for 
NQO1. We have previously shown that cyanoenones react with 
cysteine residues in Keap1, the main negative regulator of 
Nrf2.
6,7,14
  In a variety of cell lines and animal tissues, we have 
demonstrated that Nrf2 activation by cyanoenones leads to the 
coordinate transcriptional upregulation of NQO1 together with 
other Nrf2-target genes, such as multiple isoforms of glutathione 
S-transferase (GST), heme oxygenase 1, -glutamyl cysteine 
ligase catalytic (GCLC) subunit, as well as an ARE-luciferase 
reporter, a direct readout of Nrf2-mediated transcription.
6,7,14
  
Furthermore, Nrf2 is required for the NQO1 inducer activity of 
cyanoenones as NQO1 induction is not observed in Nrf2-
deficient cells.
6,7
  
The electron affinity of these new compounds can be 
calculated via the energy of their lowest unoccupied molecular 
orbital, E (LUMO) in eV, and was quantified at two quantum 
mechanical levels: the semiempirical AM1,
16
 and the density 
functional theory (DFT)
17
 (see Table 1).  Briefly, no solvent 
 
Table 1.
 
Compd#
a
 Structure pCD
b
 E (LUMO) 
AM1
c
 [eV] 
E (LUMO) 
DFT
d
 [eV] 
 
1 
(TBE-31) 
 
 
9.04 
 
–1.2576 
 
–3.0814 
 
2 
 
 
8.12 
 
–1.2017 
 
–2.9450 
 
3 
 
 
7.74 
 
 
–1.1735 
 
–2.9566 
 
4 
 
 
7.74 
 
–1.1540 
 
–2.9429 
 
5 
 
 
7.70 
 
–1.0204 
 
–2.9314 
 
6 
 
 
7.67 
 
–1.0076 
 
–2.8759 
 
7 
 
 
7.52 
 
–1.1794 
 
–2.9096 
 
8 
 
 
7.48 
 
–0.9497 
 
–2.7263 
 
9 
 
 
7.38 
 
–0.9845 
 
–2.8550 
 
10 
 
 
7.25 
 
–0.9257 
 
–2.7208 
 
11 
 
 
7.00 
 
–0.7791 
 
–2.7309 
 
12 
 
 
7.00 
 
–0.9026 
 
–2.7056 
 
13 
 
 
6.82 
 
–0.9307 
 
–2.7589 
 
14 
 
 
6.82 
 
–0.9143 
 
–2.6855 
 
15 
 
 
6.80 
 
–0.8224 
 
–2.6710 
 
16 
 
 
6.74 
 
–1.0863 
 
–3.0365 
 
17 
 
 
5.72 
 
–0.6147 
 
–2.4689 
a
These compounds are racemic or optically inactive (meso compounds). 
b
Logarithm of the reciprocal of CD values expressed in M units and reported 
in references (5) and (6). 
c,d
E (LUMO) in eV calculated using the AM1
16
 or the DFT
17
 approaches, with 
the Gaussian 09 program.
30
 
  
model was used for the calculation of the LUMO energies. Since 
the molecules are neutral and mainly non polar, we do not expect 
any significant change in the relative LUMO energies upon the 
application of an implicit solvent model. All molecules were 
fully energy-optimized before LUMO energy calculations, both 
at the DFT and AM1 levels, using the “Opt=Tight” keyword of 
the Gaussian 09 program. Since the molecules have few 
conformational degrees of freedom, we consider that this energy 
minimization is sufficient. 
Recent examples demonstrate the continuing growth of 
predictive QSAR modeling using quantum-chemical methods for 
the analysis of physico-chemical properties of congeneric series 
of chemicals that govern their biological and medicinal 
properties.
18,19
  In addition to pursuit for the QSAR between 
electron affinity and biological potency of  the tri-, bi-, and 
monocyclic compounds, the present study has another aim, that 
is, to check if the AM1 quantum mechanical procedure is as 
relevant as DFT quantum mechanical method for this type of 
application.  This question is still controversial, since fast AM1 
calculations are frequently underrated, due to the domination of 
heavy DFT calculations; as stated in a Nature article: "The DFT 
method is the most heavily cited concept in physical sciences. It 
can be used to describe all chemistry, biochemistry, biology, 
nanosystems and materials."
20 
Since tri-, bi-, and monocyclic compounds under study 
interact via their Michael acceptors with sulfhydryl groups of the 
protein Keap1, the critical feature involved in this interaction is 
their electron–acceptor property, which can be expressed by their 
reduction potential E (T/T
•-
, T = a compound of these tri-, bi-, 
and monocyclic compounds).  The relative electron–acceptor 
properties of a compound (T) can be represented by its electron 
affinity (EA) in the gas phase and its electrochemical reduction 
potential in solution E (T/T
•-
).  The EA of a compound (T) 
represents the energy liberated when an electron adds to T in the 
gas phase to form T
•-
.  Linear correlations between the EA within 
a series of related compounds, called congeners, and the energy 
of their lowest unoccupied molecular orbital E (LUMO) are 
presented in classical textbooks of Quantum Chemistry.
21,22 
A 
quantum mechanical calculation of E (LUMO) of T represents a 
satisfactory measure of the electron–acceptor properties of the 
molecule in question.
23
  This E (LUMO) is linearly correlated 
with the reduction potential E (T/T
•-
) in solution and with the EA 
of T in the gas phase as already demonstrated for a series of 
aromatic hydrocarbons.
24
  The fact that E (LUMO) can be 
considered as representative of the EA is initially based on 
Koopmans' theorem,
25
 and on its analysis by Angeli,
26
  
Mulliken,
27
 Dodds and McWeeny,
28
 and Heinrich et al. 
29
 
The E (LUMO) of the electrophilic tri-, bi-, and monocyclic 
compounds under study was calculated by two quantum 
mechanical techniques: the semiempirical AM1,
16
 and the density 
functional theory (DFT- B3LYP/6-31+G**) methods,
17
 using the 
Gaussian 09 program revision A.02 (Gaussian Inc., Wallingford 
CT, 2009).
30 
The software Kaleidagraph (version 3.6.4) was used for 
plotting our data and for the determination of the correlation 
coefficients r of the linear correlations observed. 
Plotting the potencies for induction of NQO1 expressed by 
pCD values of these compounds 1–17 excluding compound 16 
versus their E (LUMO) calculated by the AM1 and DFT methods 
leads to linear correlations spanning more than three orders of 
magnitude, and displayed in Figures 2 and 3.  
The linear correlation shown in Figure 2 is expressed by 
equation (1) 
pCD = 3.6268 – 3.763E (LUMO, AM1)  with a correlation 
coefficient (r) = 0.8969    (1) 
The linear correlation shown in Figure 3 is expressed by 
equation (2) 
pCD = –5.2486 – 4.4834E (LUMO, DFT)  with a correlation 
coefficient (r) = 0.9356  (2) 
Figure 2. Plot of the pCD of the monocyclic, bicyclic, and tricyclic 
compounds (logarithm of the reciprocal of CD, expressed in M (mol/L) units, 
CD being the concentration of inducer required to double the specific enzyme 
activity NQO1) versus their electron affinity expressed as their E (LUMO) in 
eV, calculated via the semiempirical AM1 method. 
Linear correlation and correlation coefficient r = 0.89687 corresponding to 
equation 1.  
Figure 3. Same as Figure 1, with E(LUMO) calculated at the DFT level. 
Linear correlation and correlation coefficient r = 0.9356 corresponding to 
equation 2.  
Notably and importantly, striking linear correlations 
excluding 16 are observed regardless of the molecule size. If the 
pCD of 16 followed the linear correlations observed for other 
compounds, its pCD values should be respectively pCD = 7.72 
and 8.36 [the value is as low as pCD (9.04) of 1 (TBE-31)] from 
equations (1) and (2).  We speculate that the reasons why the 
biological potency (6.74) of 16 is lower than expected are as 
follows.  Since it has been previously reported that 16 has the 
  
highest reactivity with a sulfhydryl group and a chloride anion in 
this series of compounds,
10
 a large portion of 16 could be 
“quenched” by abundant cellular thiols, such as the cysteine 
residue of glutathione, which is present at millimolar 
concentrations, and/or 16 could be inactivated by chloride anion 
in the cell culture medium used for biological testing.
31 
 
The two linear correlations (Figures 2 and 3) show that both 
methods of E (LUMO) calculations lead to rather similar 
correlation coefficients.  The similarities between the correlation 
coefficients r observed at the AM1 and DFT levels for the linear 
correlations displayed in Figures 2 and 3 demonstrate the 
relevance of the semiempirical AM1 method for this particular 
application in front of the heavier yet more frequently used DFT 
method, a question which was still controversial. 
The relevance of AM1 method versus the DFT method has 
also been observed in the case of other groups of 
chemoprotective molecules with correlation coefficients being in 
certain cases slightly higher for the AM1 method and in other 
cases lower than for the DFT method.  These correlation 
coefficients are reported in a review dealing with biological 
efficacy and redox properties of diphenols, phenylpropenoids, 
flavonoids, triterpenoids, benzoic and salicylic acids.
32
  For 
instance, in the case of 27 anti-inflammatory molecules (12 
salicylic acids and 15 phenols) the semiempirical AM1 method 
gives a better correlation coefficient r than the DFT procedure.
 32
 
In summary, we observed striking linear correlations [r  = 
0.897 (AM1) and 0.936 (DFT)] between NQO1 inducer potency 
(pCD) of these tri-, bi-, and monocyclic compounds and their E 
(LUMO) regardless of the molecule size. Importantly and 
interestingly, this finding demonstrates that the electron affinity 
is the essentially important factor for the cyanoenones to 
reversibly bind with Keap1.  Consequently, we could clarify that 
1 (TBE-31) is the most potent inducer because the both E 
(LUMO, AM1) and E (LUMO, DFT) for 1 are the lowest.  This 
QSAR encourages the design of new reversible covalent drugs 
containing cyanoenones as warheads. 
Also, our investigations indicate (i) that the semiempirical 
AM1 quantum mechanical procedure is as relevant as the density 
functional theory (DFT) quantum mechanical method for this 
application dealing with cyanoenone compounds, and (ii) that 
simple low-cost in silico determination of the electron affinity of 
candidate molecules in a set of congeners can potentially reduce 
the number of bioassays and improve the forward search for 
novel chemoprotective drugs.   
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